Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. World J Gastroenterol 2014; 20(41): 15387-15397 [PMID: 25386089 DOI: 10.3748/wjg.v20.i41.15387]
Corresponding Author of This Article
Lai Wei, MD, Professor, Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, No. 11 Xizhimen South Street, Beijing 100044, China. weilai@pkuph.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. World J Gastroenterol 2014; 20(41): 15387-15397 [PMID: 25386089 DOI: 10.3748/wjg.v20.i41.15387]
World J Gastroenterol. Nov 7, 2014; 20(41): 15387-15397 Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15387
Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients
Bo Feng, Wei Zhang, Bi-Fen Luo, Guang-Jun Song, Jian Wang, Qian Jin, Hong Qin, Lai Wei
Bo Feng, Wei Zhang, Bi-Fen Luo, Guang-Jun Song, Jian Wang, Qian Jin, Hong Qin, Lai Wei, Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing 100044, China
Author contributions: Feng B contributed to study design, data acquisition, statistical analysis and drafted the manuscript; Zhang W contributed to data acquisition and statistical analysis; Luo BF and Song GJ participated in study planning and statistical analysis; Wang J participated in study design and data analysis; Jin Q and Qin H contributed to data acquisition and statistical analysis; Wei L participated in study design, funding analysis and manuscript drafting; and all authors read and approved the final manuscript.
Supported by National S and T Major Project for Infectious Diseases Control, No. 2012ZX10002-003; National Major S and T Special Project for “Significant New Drugs Development”, No. 2012ZX09303-019; and Beijing Natural Science Foundation, No. 7122191
Correspondence to: Lai Wei, MD, Professor, Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, No. 11 Xizhimen South Street, Beijing 100044, China. weilai@pkuph.edu.cn
Telephone: +86-10-88325566 Fax: +86-10-68322662
Received: January 19, 2014 Revised: March 25, 2014 Accepted: June 26, 2014 Published online: November 7, 2014 Processing time: 295 Days and 8 Hours
Core Tip
Core tip: Hematologic abnormalities caused by hypersplenism and interferon-α (IFN-α) severely affect IFN-α-based therapy in cirrhotic patients with hepatitis C virus (HCV) infection. Splenectomy and partial splenic embolization followed by IFN-α-based therapy have been increasingly performed to address cytopenias, including thrombocytopenia, in patients with HCV-related cirrhosis with hypersplenism. However, the therapeutic effect and long-term safety of such treatments remain controversial. We performed a systematic review and demonstrated that spleen operation can improve hematologic parameters before and during IFN-α-based antiviral therapy in cirrhotic patients infected with HCV. However, this treatment is more suitable for patients with genotypes 2/3 HCV infection than for those with genotype 1.
